Today’s update highlights the strong development and commercial progress made during the year, including positive data from the first patient cohort in the Phase IIa Retinitis Pigmentosa trial (data on an all 12 patients expected in H2 2019) and the start of dosing in the Phase IIb ‘PISCES III’ trial in stroke disability (results expected H2 2020, from H1 2020). The company remains in active commercial discussions for all current programmes. We reiterate our positive stance.
08 May 2019
Year-end update: strong development & commercial progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Year-end update: strong development & commercial progress
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
08 May 2019 -
Author:
Jens Lindqvist -
Pages:
3
Today’s update highlights the strong development and commercial progress made during the year, including positive data from the first patient cohort in the Phase IIa Retinitis Pigmentosa trial (data on an all 12 patients expected in H2 2019) and the start of dosing in the Phase IIb ‘PISCES III’ trial in stroke disability (results expected H2 2020, from H1 2020). The company remains in active commercial discussions for all current programmes. We reiterate our positive stance.